Tandem Diabetes Care (NASDAQ:TNDM) Stock Gets Price Target Boost from Barclays

Tandem Diabetes Care (NASDAQ:TNDM) had its price objective upped by Barclays from $18.00 to $20.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the medical device company’s stock. Barclays‘s price target would suggest a potential upside of 20.31% from the company’s previous close.

Several other brokerages have also recently issued reports on TNDM. Mizuho set a $20.00 price objective on shares of Tandem Diabetes Care in a research note on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a research note on Tuesday, September 8th. UBS Group started coverage on shares of Tandem Diabetes Care in a report on Tuesday, July 28th. They set a “neutral” rating and a $18.00 target price for the company. William Blair assumed coverage on shares of Tandem Diabetes Care in a report on Friday, August 21st. They set an “outperform” rating for the company. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $26.00 price target (down from $30.00) on shares of Tandem Diabetes Care in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Hold” and a consensus target price of $27.18.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM traded down $1.37 during mid-day trading on Friday, reaching $16.62. 2,307,745 shares of the stock were exchanged, compared to its average volume of 2,138,377. The company has a current ratio of 3.18, a quick ratio of 2.65 and a debt-to-equity ratio of 4.62. The business has a fifty day moving average price of $17.74 and a 200 day moving average price of $18.90. Tandem Diabetes Care has a 1-year low of $12.26 and a 1-year high of $29.65. The firm has a market capitalization of $1.16 billion, a PE ratio of -17.88 and a beta of 1.59.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15. Tandem Diabetes Care had a negative net margin of 6.08% and a negative return on equity of 45.97%. The company had revenue of $283.69 million during the quarter, compared to the consensus estimate of $265.85 million. During the same period in the prior year, the company earned ($0.31) EPS. Tandem Diabetes Care’s revenue was up 13.8% on a year-over-year basis. Research analysts expect that Tandem Diabetes Care will post -0.66 earnings per share for the current fiscal year.

Insider Activity at Tandem Diabetes Care

In related news, Director Christopher J. Twomey sold 1,700 shares of the stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total value of $32,555.00. Following the completion of the transaction, the director owned 24,434 shares in the company, valued at $467,911.10. This trade represents a 6.50% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Tandem Diabetes Care

Several institutional investors and hedge funds have recently bought and sold shares of TNDM. Integrated Wealth Concepts LLC purchased a new stake in Tandem Diabetes Care during the second quarter valued at about $33,000. Sterling Capital Management LLC boosted its holdings in shares of Tandem Diabetes Care by 849.0% in the third quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock worth $38,000 after buying an additional 2,080 shares during the period. Fulcrum Asset Management LLP boosted its holdings in shares of Tandem Diabetes Care by 1,463.6% in the third quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock worth $73,000 after buying an additional 4,098 shares during the period. Provenance Wealth Advisors LLC purchased a new position in shares of Tandem Diabetes Care in the third quarter worth approximately $158,000. Finally, Prosperitas Financial LLC purchased a new position in shares of Tandem Diabetes Care in the second quarter worth approximately $151,000.

Tandem Diabetes Care News Summary

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Third-quarter revenue was $283.7 million, up 13.8% year over year and above analyst expectations. The loss of $0.10 per share was also narrower than estimates, while gross margin rose to 57%—up 270 basis points year over year. Tandem third-quarter 2026 results
• Positive Sentiment: Management projected 2026 sales of $1.065 billion to $1.085 billion, supporting the growth outlook. 2026 sales outlook and CEO transition
• Neutral Sentiment: Jeannette Bankes was named president and CEO, with the transition set for the end of 2026 as John Sheridan retires. A named successor provides clarity, though investors may watch for execution through the handoff. CEO appointment
• Negative Sentiment: Wells Fargo lowered its price target from $27 to $25, a sign of a more cautious valuation view, although it kept an Overweight rating and the revised target remains above the quoted share price. Wells Fargo price target update

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to help automate and simplify insulin therapy while supporting integration with continuous glucose monitoring (CGM) technology.

Tandem’s product portfolio includes the t:slim X2 Insulin Pump and the compact Tandem Mobi system, along with insulin cartridges, infusion sets, accessories and diabetes management software.